Mednet Logo

Should we repeat a dose-escalation trial for stage III NSCLC in the era of modern radiotherapy techniques and dose constraints?

Would you consider a 2x2 design incorporating immunotherapy?
1 Answer
Mednet Member
Mednet Member
Radiation Oncology · Michigan Healthcare Professionals, PC
Answered on

Yes to a study with modern techniques. The outcome was so odd that high dose was killing patients at a higher rate than with standard dose, despite many phase II and retrospective studies showing good outcomes. The subset analyses showing that IMRT was associated with better outcomes as well as more...

Join for free or sign in to see the full answer